导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.85% | 521/4773 |
| 近一周 | -0.17% | 954/5465 |
| 近一月 | -7.79% | 4683/5421 |
| 近一季 | -12.15% | 4017/5231 |
| 近半年 | 13.32% | 421/4920 |
| 近一年 | 20.57% | 500/4394 |
| 近两年 | 111.52% | 512/2954 |
| 近三年 | 61.20% | 461/2253 |
| 成立以来 | 77.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.76% 2895/4961 |
53.62% 513/5312 |
- - |
- - |
| 2025 | 44.12% 639/4813 |
3.10% 1195/3635 |
1.08% 2469/4076 |
40.21% 770/4524 |
-1.37% 2911/4813 |
| 2024 | 1.54% 2001/3463 |
-5.62% 1933/2808 |
-6.45% 1954/3014 |
15.31% 1753/3129 |
-0.26% 1362/3463 |
| 2023 | -11.55% 1412/2656 |
11.24% 345/2280 |
-4.70% 1258/2385 |
-11.54% 2072/2515 |
-5.68% 1461/2655 |
| 2022 | -26.37% 1394/2207 |
-19.41% 1454/1919 |
5.61% 860/2016 |
-16.62% 1478/2113 |
3.76% 648/2208 |
| 2021 | 4.16% 591/1822 |
-8.98% 1098/1255 |
17.98% 177/1330 |
-8.10% 1101/1466 |
5.54% 285/1822 |
| 2020 | 58.76% 133/1250 |
4.45% 72/1028 |
25.55% 151/1067 |
3.18% 994/1164 |
17.33% 131/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.81% 286/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 诺德研发创新100 VS. 长安沪深300非周期A(740101) |